Immuneering Corporation has presented updated clinical data on its lead candidate, atebimetinib, in combination with modified gemcitabine and nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer. According to interim results from a Phase 2a study (N=34), the combination therapy demonstrated a 94% overall survival $(OS)$ rate at six months and an 86% OS rate at nine months, as of the August 26, 2025 data cutoff. These rates compare to historical data for standard-of-care gemcitabine and nab-paclitaxel, which showed 67% and approximately 47% OS at six and nine months, respectively. The median OS for the study cohort has not yet been reached, with a median follow-up of nine months. The company also reported that the combination therapy was favorably tolerated and is advancing to further clinical studies in pancreatic and lung cancer. You can access the full presentation through the link below.